World Health Organization & Mapp Biopharmaceutical

World Health Organization: The World Health Organization recommended prioritizing three experimental treatments and several vaccine candidates for the Bundibugyo strain of Ebola, and is working with authorities to design and implement clinical trials.

Mapp Biopharmaceutical: Mapp Biopharmaceutical developed MBP134, one of the experimental treatments prioritized by the World Health Organization for the Bundibugyo strain of Ebola.

World Health Organization: The World Health Organization>>> has declared the Ebola outbreak a public health emergency of international concern and is coordinating the international response, providing experts, supplies, and guidance, though it faces criticism for delayed detection and underestimation of the outbreak's scale.

Mapp Biopharmaceutical: Mapp Biopharmaceutical>>>'s pan-ebolavirus antibody drug, MBP134, is a potential candidate for clinical trials against the Uganda — Bundibugyo strain, with development backed by BARDA.